Association of HLA-DRB1 and DQB1 alleles with different clinical manifestations. Results are shown as no. (%) of alleles.
| HLA Alleles | Diffuse SSc, n = 30 (%) | Limited SSc, n = 70 (%) | OR | p Corrected* |
|---|---|---|---|---|
| DRB 1*04 | 3 (5) | 21 (15) | 0.190 | 0.099 |
| DRB1*07 | 8 (13) | 5 (3.5) | 3.782 | 0.270 |
| DRB1*11 | 14 (23.3) | 19 (13.6) | 1.750 | 0.251 |
| DRB 1*1104 | 11 (18.3) | 6 (4.2) | 4.921 | 0.090 |
| Anti-Topo I Positive, n = 21 (%) | Anti-Topo I Negative, n = 78 (%) | |||
| DRB1*11 | 13 (31) | 23 (14.7) | 3.886 | 0.09 |
| DRB1*1104 | 10 (23.8) | 9 (5.7) | 6.090 | 0.01 |
| DQB1*03 | 19 (45.2) | 47 (30.1) | 5.457 | 0.085 |
| ACA Positive, n = 47 (%) | ACA Negative, n = 53 (%) | |||
| DRB1*01 | 18 (19) | 6 (5.7) | 4.754 | 0.018 |
| DRB1*14 | 5 (5.3) | 0 (0) | 2.238 | 0.18 |
| DRB1*1401 | 5 (5.3) | 0 (0) | 2.238 | 0.21 |
| DRB1*05 | 22 (23.4) | 9 (8.6) | 4.667 | 0.005 |
| DRB1*0501 | 17 (18) | 7 (6.7) | 3.958 | 0.09 |
| DRB1*0503 | 5 (5.3) | 0 (0) | 2.308 | 0.19 |
| PF, n = 23 (%) | No PF, n = 77 (%) | |||
| DRB1*11 | 10 (33) | 26 (15) | 4.385 | 0.045 |
| DRB1*1104 | 7 (23) | 13 (8) | 4.667 | 0.12 |
| DQB1*03 | 13 (43) | 54 (33) | 2.716 | 0.217 |
| DQB1*0301 | 12 (40) | 34 (21.5) | 5.412 | 0.05 |
| PAH, n = 13 (%) | No PAH, n = 87 (%) | |||
| DRB1*15 | 8 (18.2) | 5 (6) | 4.000 | 0.432 |
| DRB1*1501 | 8 (18.2) | 4 (5) | 5.143 | 0.19 |
↵* p corrected by Bonferroni test. Anti-topo-I: anti-topoisomerase I antibodies; ACA: anticentromere antibodies; PF: pulmonary fibrosis; PAH: pulmonary arterial hypertension.